We are live on
!
Find out more
HEC
Hudson Executive Capital Portfolio holdings
AUM
$151M
1-Year Est. Return
60.14%
This Fund
S&P 500
This Quarter
Est. Return
+47.62%
1 Year Est. Return
+60.14%
3 Year Est. Return
+143.92%
5 Year Est. Return
+104.85%
10 Year Est. Return
+677.02%
AUM
$939M
AUM Growth
+$241M
(+35%)
Cap. Flow
-$28.7M
Cap. Flow
% of AUM
-3.05%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
1
Reduced
2
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKYA
Akoya BioSciences
AKYA
|
+$18.2M |
| 2 |
Natera
NTRA
|
+$8.66M |
| 3 |
Blend Labs
BLND
|
+$2.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 81.32% |
| 2 | Technology | 5.67% |
| 3 | Healthcare | 4.51% |
Similar funds
SHF
CCM
DIG
BDS
MWA
WBCM
CAM
BA
Hudson Executive Capital's Q4 2022 Portfolio in Review
As of Q4 2022, Hudson Executive Capital held 8 positions worth $939M, up 35% from $698M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Hudson Executive Capital withdrew a net $28.7M in Q4 2022, closing 1 position and reducing 2 holdings. Its most notable exit was Blend Labs, an estimated $2.21M position sold in full.
By sector, the portfolio is most concentrated in Financials at 81% of assets, up from 72% a quarter earlier, followed by Technology and Healthcare.
- Hudson Executive Capital's biggest Q4 2022 reduction was Akoya BioSciences, cutting an estimated $18.2M.
- Hudson Executive Capital fully exited Blend Labs in Q4 2022, selling an estimated $2.21M.
- Hudson Executive Capital's ten largest holdings make up 100% of its $939M portfolio in Q4 2022.
- Hudson Executive Capital opened 0 new positions and closed 1 in Q4 2022.
- Hudson Executive Capital's portfolio value rose 35% quarter-over-quarter to $939M.
Based on Hudson Executive Capital's 13F filing for Q4 2022, filed 14 Feb 2023.